Mr. Frohlich is the Chief Executive Officer and a member of the Jade Biosciences Board of Directors. From June 2021 to October 2023, Mr. Frohlich served as Chief Operating Officer and, from January 2019 to June 2021, as Chief Business Officer at Chinook Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August 2023, where he was responsible for strategy, business development, commercial planning, chemistry, manufacturing and controls, quality and program management. Prior to Chinook, he held positions at Arbutus Biopharma (formerly Tekmira Pharmaceuticals), a biopharmaceutical company, most recently as Vice President of Business Development. Prior to joining Arbutus Biopharma, Mr. Frohlich worked internationally at Johnson & Johnson in various roles leading commercial strategy across all stages of product development. Mr. Frohlich serves on the board of directors of Nested Therapeutics and Borealis Biosciences. Mr. Frohlich received a B.Sc. in Biochemistry from the University of Victoria and an M.B.A. from the University of Oxford.